<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384148</url>
  </required_header>
  <id_info>
    <org_study_id>11-015</org_study_id>
    <nct_id>NCT02384148</nct_id>
  </id_info>
  <brief_title>Study of Circadian Clock Properties in Healthy Subjects, Obese and Type 2 Diabetic Patients.</brief_title>
  <official_title>Measure and Comparison of Molecular Circadian Clock Properties in Healthy Subjects, Obese and Type 2 Diabetic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <brief_summary>
    <textblock>
      The investigators aimed to characterize human circadian clockwork in healthy individuals in
      comparison to obese and type 2 diabetic subjects, employing the noninvasive experimental
      approach allowing the study of circadian profile in human individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators specifically aim to obtain and analyze the circadian profile of skin
      fibroblasts from healthy, obese and T2D subjects. Does circadian oscillator profile and its
      parameters (phase, period and amplitude) will differ between healthy individuals and obese/
      T2D patients? Skin biopsy will be performed in order to collect and culture skin fibroblast
      cells.

      In vivo bioluminescence recording will be performed in primary human skin fibroblast cells.
      The profiles obtained from 10 subjects in each group will be compared to their healthy
      counterparts.

      Bmal1and Per2 are clock genes. Lentiviral transduction of Bmal1-luciferase or Per2-luciferase
      in fibroblasts allow observation of circadian oscillations using bioluminescence assay.
      Phase, period length and amplitude are used to characterize the circadian rhythm.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of period length</measure>
    <time_frame>5 days</time_frame>
    <description>Period length will be calculated from oscillation profiles of Bmal1-luciferase or Per2-luc luciferase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of amplitude</measure>
    <time_frame>5 days</time_frame>
    <description>Amplitude will be calculated from oscillation profiles of Bmal1-luciferase or Per2-luc luciferase.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Circadian Rhythm</condition>
  <condition>Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>Healthy volunteers with no inflammation diseases, no neoplasia, no allergy to lidocaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetic non obese</arm_group_label>
    <description>Type 2 diabetic patients with HbA1c&gt;6.5%, body mass index 19-30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetic obese</arm_group_label>
    <description>Type 2 diabetic patients with HbA1c&gt;6.5%, body mass index &gt;30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>obese</arm_group_label>
    <description>Obese non diabetic patients with HbA1c&lt;6.5%, body mass index &gt;30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Circadian rhythm measurement</intervention_name>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Type 2 diabetic non obese</arm_group_label>
    <arm_group_label>Type 2 diabetic obese</arm_group_label>
    <arm_group_label>obese</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>A 2mm diameter skin biopsy is performed by a physician using standard procedure.</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Type 2 diabetic non obese</arm_group_label>
    <arm_group_label>Type 2 diabetic obese</arm_group_label>
    <arm_group_label>obese</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        One hundred normolipidemic healthy individuals, one hundred T2D subjects divided into two
        sub-groups (T2D non-obese and T2D obese) and one hundred obese non diabetic patients will
        be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 20-80

          -  consent obtained

        Exclusion Criteria:

          -  neoplasia

          -  inflammatory disease

          -  allergy to lidocaine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Geneva University Hospital</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Pagani L, Schmitt K, Meier F, Izakovic J, Roemer K, Viola A, Cajochen C, Wirz-Justice A, Brown SA, Eckert A. Serum factors in older individuals change cellular clock properties. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7218-23. doi: 10.1073/pnas.1008882108. Epub 2011 Apr 11.</citation>
    <PMID>21482780</PMID>
  </reference>
  <reference>
    <citation>Brown SA, Fleury-Olela F, Nagoshi E, Hauser C, Juge C, Meier CA, Chicheportiche R, Dayer JM, Albrecht U, Schibler U. The period length of fibroblast circadian gene expression varies widely among human individuals. PLoS Biol. 2005 Oct;3(10):e338. Epub 2005 Sep 27.</citation>
    <PMID>16167846</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Charna Dibner</investigator_full_name>
    <investigator_title>phD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

